Deerfield Management Amends BiomX Inc. Filing

TL;DR

Deerfield updated their BiomX stake filing. Keep an eye on this one.

AI Summary

Deerfield Management Company, L.P. and its affiliates have amended their Schedule 13D filing regarding BiomX Inc. as of July 11, 2024. The filing indicates a change in beneficial ownership, though specific new holdings or changes in percentage are not detailed in this excerpt. The filing is an amendment to a previous submission concerning BiomX Inc. common stock.

Why It Matters

This amendment signals a potential shift in the ownership structure or investment strategy of a significant shareholder in BiomX Inc., which could influence the company's stock performance and strategic decisions.

Risk Assessment

Risk Level: medium — Amendments to Schedule 13D filings often indicate changes in significant ownership stakes, which can lead to increased volatility or strategic shifts for the company.

Key Players & Entities

• Deerfield Management Company, L.P. (company) — Filing entity
• BiomX Inc. (company) — Subject company
• David Clark (person) — Associated with Deerfield Management
• DEERFIELD HEALTHCARE INNOVATIONS FUND II, L.P. (company) — Group member
• DEERFIELD MGMT HIF II, L.P. (company) — Group member
• DEERFIELD MGMT V, L.P. (company) — Group member
• DEERFIELD PRIVATE DESIGN FUND V, L.P. (company) — Group member

FAQ

Key Financial Figures

• $0.0001 — ame of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securiti

Filing Documents

• e663774_sc13da-biomx.htm (SC 13D/A) — 122KB
• 0001193805-24-000910.txt ( ) — 123KB

Interest

Item 5. Interest in Securities of the Issuer. Items 5(a), (b) and (c) of the Schedule 13D hereby amended and restated in their entirety as follows: (a) (1) Deerfield Mgmt V, L.P. Number of shares: 77,792,224 (comprised of shares of Common Stock, shares of Common Stock underlying Series X Preferred Stock and shares of Common Stock underlying warrants, in each case, held by Deerfield Private Design Fund V, L.P.) Percentage of Shares: 9.99 %* (2) Deerfield Private Design Fund V, L.P. Number of shares: 77,792,224 (comprised of shares of Common Stock, shares of Common Stock underlying Series X Preferred Stock and shares of Common Stock underlying warrants, in each case) Percentage of Shares: 9.99 %* (3) Deerfield Mgmt HIF II, L.P., L.P. Number of shares: 77,792,224 (comprised of shares of Common Stock, shares of Common Stock underlying Series X Preferred Stock and shares of Common Stock underlying warrants, in each case, held by Deerfield Healthcare Innovations Fund II, L.P.) Percentage of Shares: 9.99 %* (4) Deerfield Healthcare Innovations Fund II, L.P. Number of shares: 77,792,224 (comprised of shares of Common Stock, shares of Common Stock underlying Series X Preferred Stock and shares of Common Stock underlying warrants,) Percentage of Shares: 9.99 %* (5) Deerfield Management Number of shares: 155,584,448 (comprised of shares of Common Stock, shares of Common Stock underlying Series X Preferred Stock and shares of Common Stock underlying warrants, in each case, held by Deerfield Private Design Fund V, L.P. and Deerfield Healthcare Innovations Fund II, L.P.) Percentage of Shares: 9.99 %* (6) Flynn Number of shares: 155,584,448 (comprised of shares of Common Stock, shares of Common Stock underlying Series X Preferred Stock and shares of Common Stock underlying warrants, in each case, held by Deerfield Private Design Fund V, L.P. and Deerfield Healthcare Innovations Fund II, L.P.) Percentage of Shares: 9.99 %* *Throughout this report, the p

Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer

Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer.

of the Schedule 13D is hereby amended

Item 6 of the Schedule 13D is hereby amended and supplemented by adding the following: Stockholder Approval Matters and Conversion Approval On July 9, 2024, the Company disclosed that the stockholders of the Company had approved the Stockholder Approval Matters and that the Conversion Approval had been obtained at the Company’s annual meeting of stockholders held on such date. Accordingly, the Merger Warrants and the Private Placement Warrants became exercisable in accordance with their terms (subject to the beneficial ownership limitation contained therein) on such date. In addition, in accordance with the Certificate of Designation, each outstanding share of Series X Preferred Stock will become convertible at the election of the holder thereof into 1,000 shares of Common Stock, subject to certain limitations (including the beneficial ownership limitation), on July 12, 2024 and will automatically convert into 1,000 shares of Common Stock, subject to certain limitations (including the beneficial ownership limitation), on July 15, 2024. CUSIP No. 09090D103 SIGNATURE After reasonable inquiry and to the best of their knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct. Dated: July 11, 2024 DEERFIELD MGMT V, L.P. By: J.E. Flynn Capital V, LLC, General Partner By: /s/ Jonathan Isler Name: Jonathan Isler Title: Attorney-in-Fact DEERFIELD PRIVATE DESIGN FUND V, L.P. By: Deerfield Mgmt V, L.P., General Partner By: J.E. Flynn Capital V, LLC, General Partner By: /s/ Jonathan Isler Name: Jonathan Isler Title: Attorney-in-Fact DEERFIELD MGMT HIF II, L.P. By: J.E. Flynn Capital HIF II, LLC, General Partner By: /s/ Jonathan Isler Jonathan Isler, Attorney-In-Fact DEERFIELD HEALTHCARE INNOVATIONS FUND II, L.P. By: Deerfield Mgmt HIF II, L.P., General Partner By: J.E. Flynn Capital HIF II, LLC, General Partner By: /s/ Jonathan Isler Jonathan Isler,

View Full Filing

View this SC 13D/A filing on SEC EDGAR